Transactions

The below tombstones represent a select set of the transactions which JSB-Partners has advised on:

  • Partnering of
  • Phase 2 AP301/solnatide with
  • €6,000,000

  • Sale of
  • to
  • €28,000,000

  • Partnering of
  • Phase 3 APN-311 with
  • Not Disclosed

  • Partnering of
  • Phase 3 APN-311 with
  • Not Disclosed

  • Asset sale of
  • Qutenza & NP-1998 to
  • $13,000,000

  • Partnering of
  • Phase 3 APN-311 with
  • Not Disclosed

  • Partnering of
  • Phase 3 safinamide with
  • €20,000,000

  • Partnering of
  • Phase 3 safinamide with
  • Not Disclosed

  • Partnering of
  • Phase 1/2 Estybon with
  • Not Disclosed

  • In-Licensing by
  • of 2 Clinical Assets from
  • Not Disclosed

  • Partnering of
  • Phase 1 APN01 to
  • €252,000,000

  • Partnering of
  • Phase 2 Fipamezole with
  • $212,000,000

  • Partnering of
  • Phase 2 Axomadol with
  • Not Disclosed

  • Sale of
  • Pre-Clinical Oncology Program to
  • $67,000,000

  • Sale of
  • 8 Pre-Clinical & Phase 1 Assets to
  • Not Disclosed

View more ▼